HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies. (26th February 2015)

• Record Type: Journal Article
• Authors: Frange, Pierre; Assoumou, Lambert; Descamps, Diane; Chéret, Antoine; Goujard, Cécile; Tran, Laurent; Gousset, Marine; Avettand-Fenoël, Veronique; Bocket, Laurence; Fafi-Kremer, Samira; Guinard, Jerome; Morand-Joubert, Laurence; Nicot, Florence; Plantier, Jean-Christophe; Rogez, Sylvie; Wirden, Marc; Rouzioux, Christine; Meyer, Laurence; Chaix, Marie-Laure; Abel, S.; Abraham, B.; Allegre, T.; Antoniotti, A.; Armero, R.; Audhuy, B.; Aumaitre, H.; Beaucaire, G.; Beck-Wirth, G.; Berger, J.L.; Bernard, L.; Beuscart, C.; Bodard, L.; Bouchaud, O.; Boué, F.; Cabane, J.-P.; Cabie, A.; Champagne, H.; Cheneau, C.; Chennebault, J.-M.; Cheret, A.; Christian, B.; Compagnucci, A.; Daneluzzi, V.; Debab, Y.; Dellamonica, P.; Delfraissy, J.-F.; Devidas, A.; Diab, G.; Doll, J.; Drobacheff-Thebaut, M.C.; Durel, A.; Duvivier, C.; Esnault, J.-L.; Faba, L.; Froguel, E.; Garipuy, D.; Garrait, V.; Geffray, L.; Genet, C.; Genet, P.; Gerard, L.; Ghosn, J.; Girard, J-.J.; Girard, P.-M.; Godin-Collet, C.; Hochedez, P.; Hoen, B.; Houlbert, D.; Jacomet, C.; Jeantils, V.; Jidar, K.; Katlama, C.; Klement, E.; Lafeuillade, A.; Lascoux, C.; Launay, V.; Lepretre, A.; Levy, Y.; Makhloufi, D.; Malbec, D.; Martha, B.; May, T.; Merrien, D.; Miailhes, P.; Miodovski, C.; Molina, J.-M.; Morlat, P.; Mortier, E.; Neau, D.; Obadia, M.; Patey, O.; Pellegrin, J.-L.; Perronne, V.; Philibert, P.; Pialoux, G.; Pichancourt, G.; Piroth, L.; Poinsignon, Y.; Poizot-Martin, I.; Prazuck, T.; Prendki, V.; du Clary, F. Preveteau; Quinsat, D.; Raffi, F.; Regnier, A.; Reynes, J.; Rosenthal, E.; Rouveix, E.; Salmon, D.; Salanville, F.; Schmitt, J.-L.; Simon-Coutellier, A.; Sotto, A.; Souala, F.; Stein, A.; Timsit, F.; de Truchis, P.; Uludag, A.; Vaillant, O.; Verdon, R.; Verlesch-Langlin, A.; Viard, J.-P.; Vittecoq, D.; Weiss, L.; Yéni, P.; Zucman, D.; Allavena, C.; Allegre, T.; Amri, I.; Autran, B.; Bacchus, C.; Blanc, C.; Bonne, S.; Bonnet, B.; Bouchez, S.; Charlier, C.; Consigny, P.-H.; Duvivier, C.; Fourn, E.; Guiroy, F.; Huleux, T.; Katlama, C.; Lascoux-Combe, C.; Leplatois, A.; Lyavanc, T.; Molina, J.-M.; Naqvi, A.; Nembot, G.; Quertainmont, Y.; Raffi, F.; Samri, A.; Schneider, L.; Seang, S.; Seksik, B.C.P.; Shoai-Tehrani, M.; Slama, L.; Valentin, M.-A.; Yazdanpanah, Y.; Alloui, C.; Amiel, C.; André, P.; André-Garnier, E.; Anies, G.; Barin, F.; Bellecave, P.; Bettinger, D.; Bouvier-Alias, M.; Brun-Vézinet, F.; Calmy, A.; Calvez, V.; Caveng, W.; Chaillon, A.; Chapalay, S.; Charpentier, C.; Costagliola, D.; Cottalorda, J.; Delamare, C.; Delaugerre, C.; Dina, J.; Santos, G. Dos; Férré, V.; Flandre, P.; Fleury, H.; Fourati, S.; Gaille, C.; Giraudeau, G.; Guigon, A.; Haim-Boukobza, S.; Lagier, E.; Le Guillou-Guillemette, H.; Henquell, C.; Izopet, J.; Lambert-Niclot, S.; Leroux, M.; Maillard, A.; Malet, I.; Marcelin, A.-G.; Marque-Juillet, S.; Masquelier, B.; Mirand, A.; Morand, P.; Montes, B.; Mouna, L.; Noel, C.; Pallier, C.; Peytavin, G.; Pinson-Recordon, P.; Poveda, J.D.; Raymond, S.; Reigadas, S.; Roques, A.-M.; de Rougemont, A.; Roussel, C.; Schmitt, M.-P.; Schneider, V.; Schvoerer, E.; Signori-Schmuck, A.; Soulié, C.; Tamalet, C.; Tardy, J.C.; Trabaud, M.-A.; Vabret, A.; Vallet, S.; Yerly, S.;
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 70:Number 7(2015:Jul.)
• Page Start: 2084
• Page End: 2089
• Publication Date: 2015-02-26
• Subjects: HIV-1 -- resistance-associated mutations -- primary HIV infection; Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkv049
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Background: Our study describes the prevalence of transmitted drug resistance (TDR) among 1318 French patients diagnosed at the time of primary HIV-1 infection (PHI) in 2007–12. Methods: HIV-1 resistance-associated mutations (RAMs) were characterized using both the 2009 WHO list of mutations and the French ANRS algorithm. A genotypic susceptibility score was estimated for each first-line recommended ART combination. Results: Patients were mainly MSM (72.6%). Non-B variants were identified in 33.7% of patients. The proportion of TDR was estimated as 11.7% (95% CI 10.0–13.5). The prevalences of PI-, NRTI-, first-generation NNRTI and etravirine/rilpivirine-associated RAMs were 2.5%, 5.2%, 3.9% and 3.2%, respectively. Single, dual and triple class resistance was found in 9.6%, 1.0% and 1.1% of cases, respectively. Additionally, 5/331 strains isolated in 2010–12 had integrase inhibitor (II)-related RAMs (isolated E157Q mutation in all cases). TDR was more common among MSM than in other groups (12.9% versus 8.6%, P = 0.034), and in case of B versus non-B subtype infections (13.6% versus 7.9%, P = 0.002). The proportions of fully active combinations were ≥99.2%, ≥97.3% and ≥95.3% in cases of PI-, II- and NNRTI-based regimens, respectively. In 2010–12, the proportion of fully active efavirenz-based ART was lower in cases of subtype B versus non-B infection ( P = 0.021). Conclusions: Compared with our previous studies, the proportion of NRTI- and first-generation NNRTI-related TDR has continued to decline in French seroconverters. However, subtype B-infected MSM could drive the spread of resistant HIV strains. Finally, we suggest preferring PI- or II- to NNRTI-based combinations to treat PHI patients.